Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
about
Profile of certolizumab and its potential in the treatment of psoriatic arthritisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesThe interplay between inflammation and metabolism in rheumatoid arthritisProinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cellsIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perioDownregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic ArthritisThe IL-23/IL-17 axis in psoriatic arthritis.Psoriatic arthritis: current therapy and future directions.The microbiome and psoriatic arthritis.Investigational drugs for treating psoriatic arthritis.Autoimmunity in 2013.Proteomics focusing on immune markers in psoriatic arthritis.New treatments for inflammatory rheumatic disease.Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management.Apremilast for the treatment of psoriasis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Emerging drugs for psoriatic arthritis.Complement C3 as a marker of cardiometabolic risk in psoriasis.Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.Autoimmunity diseases of the skin.Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis.S100A8/A9 in psoriatic plaques from patients with psoriatic arthritisMetabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab.Novel pebbles in the mosaic of autoimmunity.Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.The characteristics of ascites in patients with POEMS syndrome.Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritisPotential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress
P2860
Q22305856-D444988C-99DC-455C-A020-FA4747B34A60Q26777084-6EB6DED5-2F1E-4E31-A59D-39D042739406Q26785751-842F5A6B-4A1D-45AB-B5EE-861EB09405FFQ33783947-8C54D8BB-F3E0-4F02-923A-023A7B70C156Q34538249-EA5CB2B9-485D-4A96-A5B4-0034B4F92013Q35133638-F8E9D5A4-C003-421B-8C78-DB4A464DFF33Q35667354-160A3C00-6320-4517-BEEA-97057F8EF51EQ37717133-68650AC8-782F-4994-80AD-5055187000A9Q38118343-18B2B33F-4A31-46DF-B831-25360BDB2CE3Q38182899-818391E4-B675-4FAD-B54D-4F65D7807211Q38206551-8DD2CBD2-AA6C-42A5-AD1C-540F8FC93129Q38211189-6F4B4A9E-C7A2-4539-84A1-CCB9E21E54BDQ38230695-EB9DF821-4D74-4A5C-AC76-600F0A62D41BQ38266252-329F9D4A-2D56-4A05-A76E-C47EAFD2F8BEQ38431361-50BFBA4D-8F72-4A53-B334-90B0D90E5441Q38561061-2B1DDC1C-CBC4-4B4B-9368-00D6475C4400Q38630548-8FA6943C-57F0-4CBF-98B6-E6B3F2831F4AQ38710642-C20696D7-6141-4DC8-97ED-0245069B8474Q39188717-D2F00FB4-4570-424C-9406-F2E10230321BQ39650675-F4DF9222-C85C-4B63-B0BB-10D4682F33DFQ41875213-F23C6D3F-ABBF-48F4-8DD4-97EEFBC25B43Q41993424-3C45131F-7A31-4115-86E9-1B15D25FEE83Q42241182-0F275D30-17A0-46A0-88E9-9C9274E7E1D0Q42770446-6A67736D-B584-416B-8D53-463D30575FEFQ43185018-8E02900E-83AB-4E6E-B00E-DC9C90DC82C2Q43727420-95B56DFE-FF62-4574-B553-A135F58AFC80Q47680814-75891A92-9328-4CB7-B636-B377F495FF8DQ48296840-13D63811-A021-40DE-AF02-C96552833924Q48339070-3CAD4166-FFF7-47FA-B0D3-41AE91E6B093Q50099588-7DA0CDD7-9371-471F-9F55-FB27CC168E59Q50318004-A0F54DE3-45A1-4D5B-820E-4E1D5C7FC3E5Q50868906-F09BC906-5E96-494E-A779-CFDBBFA3EAE0Q58727230-38D3E15C-E9BE-456C-9CB0-5AC13C84FB22Q59138077-3B34CF79-6A3F-4433-9684-1CFCBC95C0E3
P2860
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
@en
type
label
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
@en
prefLabel
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
@en
P50
P1433
P1476
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
@en
P2093
Eleonora Ballanti
Roberto Perricone
P304
P356
10.1016/J.AUTREV.2012.10.002
P577
2012-11-24T00:00:00Z